Emily A Kendall1,2, Peter J Kitonsa2, Annet Nalutaaya2, K Caleb Erisa2, James Mukiibi2, Olga Nakasolya2, David Isooba2, Yeonsoo Baik3, Katherine O Robsky3, Midori Kato-Maeda4, Adithya Cattamanchi2,4, Achilles Katamba2,5, David W Dowdy2,3. 1. Division of Infectious Diseases and Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. 2. Uganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 4. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA. 5. Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Abstract
BACKGROUND: New, sensitive diagnostic tests facilitate identification and investigation of milder forms of tuberculosis (TB) disease. We used community-based TB testing with the Xpert MTB/RIF Ultra assay ("Ultra") to characterize individuals with previously undiagnosed TB and compare them to those from the same community who were diagnosed with TB through routine care. METHODS: We offered community-based sputum Ultra testing to adult residents of a well-defined area (population 34 000 adults) in Kampala, Uganda, via door-to-door screening and venue-based testing, then used detailed interview and laboratory testing to characterize TB-positive individuals. We compared these individuals to residents diagnosed with pulmonary TB at local health facilities and a representative sample of residents without TB (controls). RESULTS: Of 12 032 residents with interpretable Ultra results, 113 (940 [95% confidence interval {CI}, 780-1130] per 100 000) tested positive, including 71 (63%) positive at the lowest (trace) level. A spectrum of TB disease was observed in terms of chronic cough (93% among health facility-diagnosed cases, 77% among residents with positive community-based Ultra results at levels above trace, 33% among trace-positive community participants, and 18% among TB-negative controls), TB symptom prevalence (99%, 87%, 60%, and 38%, respectively), and C-reactive protein (75th percentile: 101 mg/L, 28 mg/L, 6 mg/L, and 4 mg/L, respectively). Community-diagnosed cases were less likely than health facility-diagnosed cases to have human immunodeficiency virus coinfection or previous TB. The specificity of Ultra was 99.4% (95% CI, 99.2%-99.5%) relative to a single spot sputum culture. CONCLUSIONS: People with undiagnosed prevalent TB in the community have different characteristics than those diagnosed with pulmonary TB in health facilities. Newer diagnostic tests may identify a group of people with early or very mild disease.
BACKGROUND: New, sensitive diagnostic tests facilitate identification and investigation of milder forms of tuberculosis (TB) disease. We used community-based TB testing with the Xpert MTB/RIF Ultra assay ("Ultra") to characterize individuals with previously undiagnosed TB and compare them to those from the same community who were diagnosed with TB through routine care. METHODS: We offered community-based sputum Ultra testing to adult residents of a well-defined area (population 34 000 adults) in Kampala, Uganda, via door-to-door screening and venue-based testing, then used detailed interview and laboratory testing to characterize TB-positive individuals. We compared these individuals to residents diagnosed with pulmonary TB at local health facilities and a representative sample of residents without TB (controls). RESULTS: Of 12 032 residents with interpretable Ultra results, 113 (940 [95% confidence interval {CI}, 780-1130] per 100 000) tested positive, including 71 (63%) positive at the lowest (trace) level. A spectrum of TB disease was observed in terms of chronic cough (93% among health facility-diagnosed cases, 77% among residents with positive community-based Ultra results at levels above trace, 33% among trace-positive community participants, and 18% among TB-negative controls), TB symptom prevalence (99%, 87%, 60%, and 38%, respectively), and C-reactive protein (75th percentile: 101 mg/L, 28 mg/L, 6 mg/L, and 4 mg/L, respectively). Community-diagnosed cases were less likely than health facility-diagnosed cases to have human immunodeficiency virus coinfection or previous TB. The specificity of Ultra was 99.4% (95% CI, 99.2%-99.5%) relative to a single spot sputum culture. CONCLUSIONS:People with undiagnosed prevalent TB in the community have different characteristics than those diagnosed with pulmonary TB in health facilities. Newer diagnostic tests may identify a group of people with early or very mild disease.
Authors: Guy B Marks; Nhung V Nguyen; Phuong T B Nguyen; Thu-Anh Nguyen; Hoa B Nguyen; Khoa H Tran; Son V Nguyen; Khanh B Luu; Duc T T Tran; Qui T N Vo; Oanh T T Le; Yen H Nguyen; Vu Q Do; Paul H Mason; Van-Anh T Nguyen; Jennifer Ho; Vitali Sintchenko; Linh N Nguyen; Warwick J Britton; Greg J Fox Journal: N Engl J Med Date: 2019-10-03 Impact factor: 91.245
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: Katherine O Robsky; Peter J Kitonsa; James Mukiibi; Olga Nakasolya; David Isooba; Annet Nalutaaya; Phillip P Salvatore; Emily A Kendall; Achilles Katamba; David Dowdy Journal: Infect Dis Poverty Date: 2020-06-22 Impact factor: 4.520
Authors: Emily A Kendall; Caleb Kamoga; Peter J Kitonsa; Annet Nalutaaya; Phillip P Salvatore; Katherine Robsky; Olga Nakasolya; James Mukiibi; David Isooba; Adithya Cattamanchi; Midori Kato-Maeda; Achilles Katamba; David W Dowdy Journal: PLoS One Date: 2019-07-24 Impact factor: 3.240
Authors: Katherine O Robsky; Seamus Hughes; Alex Kityamuwesi; Emily A Kendall; Peter James Kitonsa; David W Dowdy; Achilles Katamba Journal: BMC Infect Dis Date: 2020-06-11 Impact factor: 3.090
Authors: Elizabeth L Corbett; Tsitsi Bandason; Trinh Duong; Ethel Dauya; Beauty Makamure; Gavin J Churchyard; Brian G Williams; Shungu S Munyati; Anthony E Butterworth; Peter R Mason; Stanley Mungofa; Richard J Hayes Journal: Lancet Date: 2010-10-09 Impact factor: 79.321
Authors: Soumitesh Chakravorty; Ann Marie Simmons; Mazhgan Rowneki; Heta Parmar; Yuan Cao; Jamie Ryan; Padmapriya P Banada; Srinidhi Deshpande; Shubhada Shenai; Alexander Gall; Jennifer Glass; Barry Krieswirth; Samuel G Schumacher; Pamela Nabeta; Nestani Tukvadze; Camilla Rodrigues; Alena Skrahina; Elisa Tagliani; Daniela M Cirillo; Amy Davidow; Claudia M Denkinger; David Persing; Robert Kwiatkowski; Martin Jones; David Alland Journal: mBio Date: 2017-08-29 Impact factor: 7.867
Authors: Beatrice Frascella; Alexandra S Richards; Bianca Sossen; Jon C Emery; Anna Odone; Irwin Law; Ikushi Onozaki; Hanif Esmail; Rein M G J Houben Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079
Authors: K O Robsky; J Mukiibi; A Nalutaaya; P J Kitonsa; D Isooba; O Nakasolya; Y Baik; C E Kamoga; E A Kendall; A Katamba; D W Dowdy Journal: Int J Tuberc Lung Dis Date: 2021-06-01 Impact factor: 2.373
Authors: Ruvandhi R Nathavitharana; Alberto L Garcia-Basteiro; Morten Ruhwald; Frank Cobelens; Grant Theron Journal: EBioMedicine Date: 2022-03-23 Impact factor: 11.205
Authors: Jana Fehr; Stefan Konigorski; Stephen Olivier; Resign Gunda; Ashmika Surujdeen; Dickman Gareta; Theresa Smit; Kathy Baisley; Sashen Moodley; Yumna Moosa; Willem Hanekom; Olivier Koole; Thumbi Ndung'u; Deenan Pillay; Alison D Grant; Mark J Siedner; Christoph Lippert; Emily B Wong Journal: NPJ Digit Med Date: 2021-07-02